Literature DB >> 33780043

A noncanonical FLT3 gatekeeper mutation disrupts gilteritinib binding and confers resistance.

Sunil K Joshi1,2,3, Setareh Sharzehi1,3,4, Janét Pittsenbarger1,3, Daniel Bottomly1,5, Cristina E Tognon1,3, Shannon K McWeeney1,5, Brian J Druker1,3,4, Elie Traer1,3,4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 33780043     DOI： 10.1002/ajh.26174

Source DB:  PubMed          Journal:  Am J Hematol        ISSN： 0361-8609            Impact factor:   10.047


× No keyword cloud information.
  4 in total

1.  Understanding gilteritinib resistance to FLT3-F691L mutation through an integrated computational strategy.

Authors:  Shibo Zhou; Bo Yang; Yufeng Xu; Aihua Gu; Juan Peng; Jinfeng Fu
Journal:  J Mol Model       Date:  2022-08-06       Impact factor: 2.172

2.  Exploring the Resistance Mechanisms of Distal D835V Mutation in FLT3 to Inhibitors.

Authors:  Zhiwei Wang; Baichun Hu; Yu An; Jian Wang
Journal:  Oxid Med Cell Longev       Date:  2022-03-28       Impact factor: 6.543

Review 3.  Developments and challenges of FLT3 inhibitors in acute myeloid leukemia.

Authors:  Shuai-Shuai Ge; Song-Bai Liu; Sheng-Li Xue
Journal:  Front Oncol       Date:  2022-09-14       Impact factor: 5.738

4.  The AML microenvironment catalyzes a stepwise evolution to gilteritinib resistance.

Authors:  Sunil K Joshi; Tamilla Nechiporuk; Daniel Bottomly; Paul D Piehowski; Julie A Reisz; Janét Pittsenbarger; Andy Kaempf; Sara J C Gosline; Yi-Ting Wang; Joshua R Hansen; Marina A Gritsenko; Chelsea Hutchinson; Karl K Weitz; Jamie Moon; Francesca Cendali; Thomas L Fillmore; Chia-Feng Tsai; Athena A Schepmoes; Tujin Shi; Osama A Arshad; Jason E McDermott; Ozgun Babur; Kevin Watanabe-Smith; Emek Demir; Angelo D'Alessandro; Tao Liu; Cristina E Tognon; Jeffrey W Tyner; Shannon K McWeeney; Karin D Rodland; Brian J Druker; Elie Traer
Journal:  Cancer Cell       Date:  2021-06-24       Impact factor: 38.585
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.